Cytori (NASDAQ:CYTX) sold its first European Union StemSource^® Cell Bank as part of an agreement with Biohellenika (www.biohellenika.gr). Biohellenika, the leading provider of cord blood stem cell banking services in Greece, will be the exclusive provider of the StemSource Cell Bank cryopreservation services in Greece, which is one of the largest markets for cell banking in Europe.

The StemSource Cell Bank is a comprehensive product offering, which allows companies or hospitals to economically process and store their clients’ adipose tissue-derived stem and regenerative cells for potential future use. The foundation of the cell bank is Cytori’s Celution^® 900 System, which automates the processing of stem and regenerative cells from adipose tissue to facilitate cryopreservation.

“Providing adults the option to preserve their cells with the StemSource Cell Bank holds great commercial promise in Greece,” said Dr. George Koliakos of Biohellenika. “We are excited about the therapeutic potential of adipose derived stem and regenerative cells and the opportunity to bank these cells from patients undergoing surgical procedures each day. As the leading provider of cord blood cell banking in Greece, we have the experience to immediately and successfully commercialize Cytori’s adipose tissue-based cell banking product.”

The StemSource Cell Bank is being marketed on Cytori’s behalf to hospitals in Japan, Korea, Taiwan, and Thailand exclusively by Green Hospital Supply (GHS). In addition, Cytori is commercializing the StemSource Cell Bank directly in Europe and the Middle East and additional countries in Asia.

About Cytori

Cytori’s (NASDAQ:CYTX) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells. The Celution^® 800 System is being introduced in Europe into the reconstructive surgery market while the Celution^® 900 System will be launched in Japan for cryopreserving a patient's own stem and regenerative cells. Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs. www.cytoritx.com

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori’s Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

Media & Investor Contact:
Cytori Therapeutics
Tom Baker, 858-875-5258
tbaker@cytoritx.com